We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 207

Supreme Court of Canada Bulletin
  • Gowling WLG
  • Canada
  • November 9 2018

Mr. Raîche, the applicant, is not represented by counsel. He instituted an action against the respondent, the Attorney General of Quebec, in 2015 for


Changes to IP rights on the horizon: Canada introduces legislation to implement CETA
  • Gowling WLG
  • Canada
  • December 21 2016

The recently signed Comprehensive Economic and Trade Agreement (CETA) between Canada and the European Union requires Canada to make changes to


Update on Vanessa’s Law: The implementation of Health Canada’s powers under the modernized Food and Drugs Act
  • Gowling WLG
  • Canada
  • July 6 2016

In my earlier article Bill C-17: modernizing the Food and Drugs Act but at what cost?, I described the potential implications of the Protecting


Drug advertising in the context of social media
  • Gowling WLG
  • USA, Canada
  • January 22 2016

Both in the U.S. and in Canada, advertising of prescription pharmaceutical products is highly regulated and can raise various challenges, which are


Data protection: defining innovative drug in Canada
  • Gowling WLG
  • Canada
  • April 22 2013

Canada amended its Data Protection Regulations in 2006 to provide protection for innovative drugs in a second attempt to implement Canada's 1994


Diet and wellness product marketers, beware: back it up!
  • Gowling WLG
  • Canada
  • October 31 2011

In recent years, the U.S. Federal Trade Commission (FTC) has paid particular attention to advertisers who have falsely promised fast and easy weight-loss results.


Federal Court upholds patent on Cellcept: found useful, non-obvious
  • Gowling WLG
  • Canada
  • July 21 2011

On July 13, 2011, Justice O’Reilly of the Federal Court granted an application commenced by Hoffmann-La Roche under the Patented Medicines (Notice of Compliance) Regulations to prohibit the Minister of Health from issuing a NOC to Apotex Inc. for its generic version of the brand drug, Cellcept (mycophenolate mofetil (“MMF”)), until the expiry of Hoffmann-La Roche’s Canadian Patent 1,333, 285.


Supreme Court denies leave to challenge validity of Canada's data protection regulations
  • Gowling WLG
  • Canada
  • July 14 2011

Today, the Supreme Court of Canada denied leave to Apotex Inc. and the Canadian Generic Pharmaceutical Association, refusing to hear an appeal that would question the validity of the data protection regulations (section C.08.004.1 of Canada's Food and Drug Regulations).


The Canada Consumer Product Safety Act came into force on June 20, 2011
  • Gowling WLG
  • Canada
  • July 13 2011

The CCPSA prohibits the sale of unsafe products, requires support for safety and compliance with the CCPSA, requires record keeping, and requires mandatory incident reporting.


Motion for interlocutory injunction in patent case and appeal (esomeprazole)
  • Gowling WLG
  • Canada
  • July 7 2011

The Federal Court of Appeal has upheld a decision to deny an innovator pharmaceutical company's motion for an interlocutory injunction prior to the trial of an infringement action, scheduled to be heard in September 2013.